Compare DaVita’s recalibrated outlook with a hand picked group of healthcare providers facing similar reimbursement and volume pressures through the 36 healthcare AI stocks.
To own DaVita, you need to be comfortable with a story where steady dialysis demand and Integrated Kidney Care offset ongoing reimbursement friction and payer mix shifts. The analyst consensus Narrative on Simply Wall St leans on earnings support from IKC and technology driven efficiency. The latest outlook for lower fourth quarter treatments, partly calendar driven, does not materially alter that bigger picture. However, it keeps the focus squarely on revenue per treatment.
In the short term, the key swing factor is how effectively DaVita converts higher revenue per treatment and IKC contribution into operating income while absorbing a roughly US$70 million foreign exchange headwind. The biggest risk still sits in reimbursement and mix pressure, including expected ACA related headwinds in 2026 and 2027, along with rising G&A that has been growing at a double digit rate.
The most relevant fresh data point is DaVita’s commentary that higher revenue per treatment should help offset the expected fourth quarter decline in dialysis sessions. That ties directly into the current catalyst list, where IKC savings and dialyzer deployment are intended to support earnings even when treatment growth is modest. You are essentially watching whether pricing and care management can do more of the heavy lifting.
The upcoming UBS Global Healthcare and Wolfe Research conferences give management public stages to reaffirm or refine that message. Investors will likely listen for detail on the 1.5% to 2% Medicare rate assumption, the US$70 million currency headwind, and how much Integrated Kidney Care can add to adjusted operating income in 2026. Clear commentary on cost discipline and payer mix would help you assess whether the existing catalyst and risk balance still holds.
DaVita's narrative projects US$16.1b revenue and US$1.1b earnings by 2029. That path assumes 4.6% yearly revenue growth and an earnings increase of about US$277.5m from current earnings of US$822.5m.
Uncover why DaVita's fair value indicates a 26% potential upside to its current price that could narrow quickly.
Some of the most optimistic analysts focus on DaVita’s AI and technology programmes as a future cost saver rather than just an expense line. Before this new treatment and conference update, they were pencilling in roughly 5.7% yearly revenue growth and about US$1.1b in earnings by 2029. Those projections may be revisited, so it helps to compare this upbeat view with more cautious takes before considering how the story might evolve.
Explore 3 other DaVita fair value estimates, including one that suggests potential upside of as much as 115% from the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Once you have formed a view on DaVita, it often helps to widen the lens and compare it with other companies that fit different risk and income profiles. The Simply Wall St Screener can surface focused shortlists in a few clicks so you are not starting from a blank page.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com